A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-Positive Primary Breast Cancer|Residual Invasive Breast Cancer
Interventions: DRUG: DS-8201a|DRUG: T-DM1
Sponsor: Daiichi Sankyo
Collaborators: AstraZeneca|NSABP Foundation Inc|German Breast Group|Spanish Breast Cancer Research Group (SOLTI)